In This Article:
It's been a soft week for CorMedix Inc. (NASDAQ:CRMD) shares, which are down 23%. But that doesn't detract from the splendid returns of the last year. Like an eagle, the share price soared 188% in that time. So some might not be surprised to see the price retrace some. The real question is whether the business is trending in the right direction.
In light of the stock dropping 23% in the past week, we want to investigate the longer term story, and see if fundamentals have been the driver of the company's positive one-year return.
Check out our latest analysis for CorMedix
Given that CorMedix didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
In the last year CorMedix saw its revenue grow by 41,184%. That's well above most other pre-profit companies. And the share price has responded, gaining 188% as we previously mentioned. That sort of revenue growth is bound to attract attention, even if the company doesn't turn a profit. The strong share price rise indicates optimism, so there may be a better opportunity for buyers as the hype fades a bit.
The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).
This free interactive report on CorMedix's balance sheet strength is a great place to start, if you want to investigate the stock further.
A Different Perspective
It's good to see that CorMedix has rewarded shareholders with a total shareholder return of 188% in the last twelve months. That gain is better than the annual TSR over five years, which is 14%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It's always interesting to track share price performance over the longer term. But to understand CorMedix better, we need to consider many other factors. Take risks, for example - CorMedix has 3 warning signs we think you should be aware of.
We will like CorMedix better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.